Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
暂无分享,去创建一个
[1] S. Dimmeler,et al. Endothelial Progenitor Cells: Characterization and Role in Vascular Biology , 2004, Circulation research.
[2] Christoph Dehio,et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.
[3] L. Naldini,et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells , 2003, Nature Medicine.
[4] P. Carmeliet. Angiogenesis in health and disease , 2003, Nature Medicine.
[5] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[6] P. Ratcliffe,et al. Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.
[7] D. Hanahan,et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.
[8] Christie M. Orschell,et al. Peripheral Blood “Endothelial Progenitor Cells” Are Derived From Monocyte/Macrophages and Secrete Angiogenic Growth Factors , 2003, Circulation.
[9] K. Sugimachi,et al. Angiogenic switch as a molecular target of malignant tumors. , 2003, Journal of gastroenterology.
[10] J. Haigh,et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.
[11] A. Luttun,et al. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? , 2003, The Journal of clinical investigation.
[12] T. Libermann,et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .
[13] J. Feige,et al. Thrombospondins as anti-angiogenic therapeutic agents. , 2003, Current pharmaceutical design.
[14] Kenneth J. Hillan,et al. Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 , 2003, Science.
[15] T. H. van der Kwast,et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma , 2003, Journal of clinical pathology.
[16] D. Ribatti,et al. Analysis of the role of chemokines in angiogenesis. , 2003, Journal of immunological methods.
[17] P. Carmeliet,et al. A critical role of placental growth factor in the induction of inflammation and edema formation. , 2003, Blood.
[18] R. Jain. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. , 2002, Seminars in oncology.
[19] J. Folkman. Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.
[20] S. Rafii. Vaccination against tumor neovascularization: Promise and reality. , 2002, Cancer cell.
[21] D. Mukhopadhyay,et al. KDR Stimulates Endothelial Cell Migration through Heterotrimeric G Protein Gq/11-mediated Activation of a Small GTPase RhoA* , 2002, The Journal of Biological Chemistry.
[22] Lee Chao,et al. Kallistatin is a new inhibitor of angiogenesis and tumor growth. , 2002, Blood.
[23] W. Bellamy. Vascular endothelial growth factor as a target opportunity in hematological malignancies , 2002, Current opinion in oncology.
[24] A. D. de Vos,et al. Vascular Endothelial Growth Factor–Induced Genes in Human Umbilical Vein Endothelial Cells: Relative Roles of KDR and Flt-1 Receptors , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[25] H. Dvorak. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[27] M. Teh,et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. , 2002, Experimental cell research.
[28] Tobias Sjöblom,et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. , 2002, Cancer research.
[29] Masanori Hangai,et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. , 2002, The American journal of pathology.
[30] Napoleone Ferrara,et al. VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.
[31] R. Hynes. A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.
[32] N. Voelkel,et al. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. , 2002, American journal of physiology. Lung cellular and molecular physiology.
[33] P. Richardson,et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment , 2002, Cancer research.
[34] P. Campochiaro,et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. , 2002, Developmental cell.
[35] F. Rickles,et al. Tissue factor and angiogenesis in cancer , 2002, Current opinion in hematology.
[36] G. Berchem,et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis , 2002, Oncogene.
[37] M. Corada,et al. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. , 2002, Blood.
[38] P. Campochiaro,et al. Angiopoietin‐2 plays an important role in retinal angiogenesis , 2002, Journal of cellular physiology.
[39] S. Donnini,et al. Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. , 2002, Cardiovascular research.
[40] S. Brodsky. Coagulation, Fibrinolysis and Angiogenesis: New Insights from Knockout Mice , 2002, Nephron Experimental Nephrology.
[41] Y. Ng,et al. Tales of the cryptic: unveiling more angiogenesis inhibitors. , 2002, Trends in molecular medicine.
[42] A. Sica,et al. Tumor-associated macrophages: a molecular perspective. , 2002, International immunopharmacology.
[43] G. Zambruno,et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. , 2002, Journal of cell science.
[44] Till Acker,et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice , 2002, Nature Medicine.
[45] Thomas N. Sato,et al. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF) , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[46] A. D. de Vos,et al. KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF , 2002, Hypertension.
[47] Lieve Moons,et al. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. , 2002, Journal of the American Society of Nephrology : JASN.
[48] M. Shibuya,et al. Tumor‐infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer , 2002, International journal of cancer.
[49] H. DeLisser,et al. Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. , 2002, American journal of physiology. Cell physiology.
[50] C. Jackson. Matrix metalloproteinases and angiogenesis , 2002, Current opinion in nephrology and hypertension.
[51] G. Yousef,et al. Expanded Human Tissue Kallikrein Family – A Novel Panel of Cancer Biomarkers , 2002, Tumor Biology.
[52] P. Carmeliet,et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.
[53] Mirna Lechpammer,et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.
[54] K. Acharya,et al. Role of placenta growth factor in cardiovascular health. , 2002, Trends in cardiovascular medicine.
[55] Peter Carmeliet,et al. Molecular mechanisms of lymphangiogenesis in health and disease. , 2002, Cancer cell.
[56] P. Carmeliet,et al. Cell Type‐Specific Expression of Neuropilins in an MCA‐Occlusion Model in Mice Suggests a Potential Role in Post‐Ischemic Brain Remodeling , 2002, Journal of neuropathology and experimental neurology.
[57] J. Isner,et al. Endothelial progenitor cells for vascular regeneration. , 2002, Journal of hematotherapy & stem cell research.
[58] N. Pavlakis,et al. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] Rakesh K Jain,et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.
[60] L. Devy,et al. The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[61] David A. Cheresh,et al. Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.
[62] A. Luttun,et al. Vascular progenitors: from biology to treatment. , 2002, Trends in cardiovascular medicine.
[63] T. Shiomi,et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF‐induced angiogenesis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[64] P. Ratcliffe,et al. Oxygen sensors and angiogenesis. , 2002, Seminars in cell & developmental biology.
[65] M. Trikha,et al. Platelets and Cancer: Implications for Antiangiogenic Therapy , 2002, Seminars in thrombosis and hemostasis.
[66] R. Strasser,et al. Phenotypic overlap between hematopoietic cells with suggested angioblastic potential and vascular endothelial cells. , 2002, Journal of hematotherapy & stem cell research.
[67] Ingeborg Stalmans,et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. , 2002, The Journal of clinical investigation.
[68] R. K. Jain,et al. Vessels of death or life. , 2001, Scientific American.
[69] W. Welch,et al. Monoclonal Antibodies to Vascular Endothelial Growth Factor (VEGF) And the VEGF Receptor, FLT-1, Inhibit the Growth of C6 Glioma in a Mouse Xenograft , 2001, Journal of Neuro-Oncology.
[70] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[71] A. Eichmann,et al. Endogenous origin of the lymphatics in the avian chorioallantoic membrane , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.
[72] P. Bornstein,et al. Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. , 2001, The American journal of pathology.
[73] E. Weinberg,et al. The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development , 2001, Mechanisms of Development.
[74] Peter Bohlen,et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. , 2001, Cancer research.
[75] K. Alitalo,et al. Lymphatic Vessels as Targets of Tumor Therapy? , 2001, The Journal of experimental medicine.
[76] S. Rafii,et al. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[77] A. Ishida,et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells , 2001, Journal of cellular physiology.
[78] P. Carmeliet,et al. Clotting Factors Build Blood Vessels , 2001, Science.
[79] D. Mukhopadhyay,et al. Vascular Permeability Factor (VPF)/Vascular Endothelial Growth Factor (VEGF) Receptor-1 Down-modulates VPF/VEGF Receptor-2-mediated Endothelial Cell Proliferation, but Not Migration, through Phosphatidylinositol 3-Kinase-dependent Pathways* , 2001, The Journal of Biological Chemistry.
[80] M. Mrksich,et al. Direct Cell Adhesion to the Angiopoietins Mediated by Integrins* , 2001, The Journal of Biological Chemistry.
[81] S. Kliche,et al. VEGF Receptor Signaling and Endothelial Function , 2001, IUBMB life.
[82] MS Pepper,et al. Extracellular Proteolysis and Angiogenesis , 2001, Thrombosis and Haemostasis.
[83] N. Ferrara. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.
[84] S. Rafii,et al. Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.
[85] Till Acker,et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.
[86] L. Devy,et al. MT1‐MMP expression promotes tumor growth and angiogenesis through an up‐regulation of vascular endothelial growth factor expression , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[87] P. Carmeliet,et al. Heterogeneous vascular dependence of tumor cell populations. , 2001, The American journal of pathology.
[88] J. Rakic,et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[89] M. Karkkainen,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. , 2001, Cancer research.
[90] W. Schaffner,et al. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. , 2001, Cancer research.
[91] M. Pepper,et al. Lymphangiogenesis and tumor metastasis: myth or reality? , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[92] D. Weng,et al. Angiozyme: A Novel angiogenesis inhibitor , 2001, Current oncology reports.
[93] Y. G. Kim,et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[94] Nils Brünner,et al. The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies , 2001 .
[95] L. Orci,et al. Vascular endothelial growth factor‐C‐mediated lymphangiogenesis promotes tumour metastasis , 2001, The EMBO journal.
[96] N. Ferrara,et al. Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) , 2001, The Journal of Biological Chemistry.
[97] L. Ellis,et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.
[98] T. Noda,et al. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. , 2001, Cancer research.
[99] Thomas Hawighorst,et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.
[100] M. Shoji,et al. The Role of the Hemostatic System in Tumor Growth, Metastasis, and Angiogenesis: Tissue factor is a Bifunctional Molecule Capable of Inducing Both Fibrin Deposition and Angiogenesis in Cancer , 2001, International journal of hematology.
[101] K. Shitara,et al. and surface marker for the lineage of monocyte-macrophages in humans Flt-1 , vascular endothelial growth factor receptor 1 , is a novel cell , 2001 .
[102] Steven A. Stacker,et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.
[103] S. Stacker,et al. Localization of vascular endothelial growth factor‐D in malignant melanoma suggests a role in tumour angiogenesis , 2001, The Journal of pathology.
[104] M. Shibuya. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.
[105] R K Jain,et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[106] S. Ekker,et al. Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. , 2000, Yeast.
[107] P. Lacal,et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. , 2000, The Journal of investigative dermatology.
[108] R K Jain,et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. , 2000, Cancer research.
[109] M Ancukiewicz,et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.
[110] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[111] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[112] P. Carmeliet,et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 , 2000, Mechanisms of Development.
[113] A. Luttun,et al. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: Insights from genetic studies , 2000, Current atherosclerosis reports.
[114] H. Blau,et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.
[115] R. Jain,et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.
[116] N. Ferrara,et al. A repressor sequence in the juxtamembrane domain of Flt‐1 (VEGFR‐1) constitutively inhibits vascular endothelial growth factor‐dependent phosphatidylinositol 3′‐kinase activation and endothelial cell migration , 2000, The EMBO journal.
[117] G. Steiner,et al. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. , 2000, The Journal of urology.
[118] J W Baish,et al. Fractals and cancer. , 2000, Cancer research.
[119] N. Rahimi,et al. Receptor Chimeras Indicate That the Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Modulates Mitogenic Activity of VEGFR-2 in Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[120] K. Shitara,et al. Properties of Two VEGF Receptors, Flt‐1 and KDR, in Signal Transduction a , 2000, Annals of the New York Academy of Sciences.
[121] S. Woo,et al. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[122] K. Shitara,et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells , 2000, Oncogene.
[123] J. Vaillant,et al. Vegf, vegf‐B, vegf‐C and their receptors KDR, FLT‐1 and FLT‐4 during the neoplastic progression of human colonic mucosa , 2000, International journal of cancer.
[124] R K Jain,et al. Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.
[125] N. Glazer,et al. Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.
[126] P. Carmeliet. Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.
[127] E. Wagner,et al. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. , 2000, Development.
[128] H. Augustin,et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.
[129] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[130] Thomas N. Sato,et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.
[131] N. Fusenig,et al. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[132] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.
[133] P. Carmeliet. Developmental biology: Controlling the cellular brakes , 1999, Nature.
[134] W. Gerald,et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts , 1999, Nature.
[135] A. Luttun,et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.
[136] G. Oliver,et al. Prox1 Function Is Required for the Development of the Murine Lymphatic System , 1999, Cell.
[137] K. Plate,et al. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas , 1999, The Journal of pathology.
[138] M. Corada,et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[139] M. Skobe,et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. , 1999, The American journal of pathology.
[140] A. Baici,et al. Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases , 1999, FEBS letters.
[141] P. Carmeliet,et al. Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis , 1999, Cell.
[142] P. Nawroth,et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[143] G. Yancopoulos,et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.
[144] Napoleone Ferrara,et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation , 1999, Nature Medicine.
[145] Willem Flameng,et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 , 1999, Nature Medicine.
[146] A. Hoffman,et al. Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[147] D. Pode,et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.
[148] Thomas N. Sato,et al. Increased vascularization in mice overexpressing angiopoietin-1. , 1998, Science.
[149] P. Krieg,et al. VEGF mediates angioblast migration during development of the dorsal aorta in Xenopus. , 1998, Development.
[150] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[151] M. Shibuya,et al. Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.
[152] T. Noda,et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[153] M. Skobe,et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.
[154] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[155] K. Alitalo,et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. , 1998, The American journal of pathology.
[156] Jessica Lo,et al. HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .
[157] P. Opolon,et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[158] E. Keshet,et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.
[159] S. Bentolila,et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. , 1998, Blood.
[160] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[161] S. Itohara,et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.
[162] Yihai Cao,et al. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1 , 1998, Oncogene.
[163] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[164] P. V. van Diest,et al. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops , 1998, The Journal of pathology.
[165] Y. Dor,et al. Ischemia-driven angiogenesis. , 1997, Trends in cardiovascular medicine.
[166] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[167] A. Harris,et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[168] Thomas N. Sato,et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.
[169] I. Takanami,et al. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. , 1997, Anticancer research.
[170] H. Granger,et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[171] Rakesh K. Jain,et al. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.
[172] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[173] Pamela F. Jones,et al. Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.
[174] W. Kaelin,et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[175] A. Ullrich,et al. Flk-1 as a target for tumor growth inhibition. , 1996, Cancer research.
[176] A. Mantovani,et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.
[177] Kenneth J. Hillan,et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.
[178] Lieve Moons,et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.
[179] M. Shibuya,et al. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[180] L. Aiello,et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[181] J. Rossant,et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.
[182] M. Shibuya,et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.
[183] M. Shibuya,et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.
[184] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[185] J. Winer,et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.
[186] T. Luther,et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. , 1994, The Journal of clinical investigation.
[187] R K Jain,et al. Barriers to drug delivery in solid tumors. , 1994, Scientific American.
[188] D. Marmé,et al. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells , 1994, Journal of cellular biochemistry.
[189] R. Kendall,et al. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[190] W. Hendrickson,et al. A structural superfamily of growth factors containing a cystine knot motif , 1993, Cell.
[191] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[192] G. Viglietto,et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[193] M. Shibuya,et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.
[194] R K Jain,et al. Determinants of tumor blood flow: a review. , 1988, Cancer research.
[195] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[196] M. Knoth,et al. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. , 1968, Journal of the National Cancer Institute.
[197] M. Greenblatt,et al. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. , 1968, Journal of the National Cancer Institute.
[198] E. Goldmann. The Growth of Malignant Disease in Man and the Lower Animals, with special reference to the Vascular System. , 1907, Proceedings of the Royal Society of Medicine.
[199] M. Matsumura,et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. , 2003, Investigative ophthalmology & visual science.
[200] Ingeborg Stalmans,et al. VEGF: A modifier of the del22q11 (DiGeorge) syndrome? , 2003, Nature Medicine.
[201] C. Betsholtz,et al. Analysis of Mural Cell Recruitment to Tumor Vessels , 2002, Circulation.
[202] M. Detmar,et al. The α1β1 and α2β1 Integrins Provide Critical Support for Vascular Endothelial Growth Factor Signaling, Endothelial Cell Migration, and Tumor Angiogenesis , 2002 .
[203] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.
[204] D. Taverna,et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.
[205] Till Acker,et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.
[206] M. Shibuya,et al. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. , 2001, Human pathology.
[207] Dian Feng,et al. Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.
[208] V. Vincenti,et al. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). , 1999, Current topics in microbiology and immunology.
[209] A. Ullrich,et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.
[210] R. Bjercke,et al. KDR activation is crucial for VEGF165-mediated Ca2+ mobilization in human umbilical vein endothelial cells. , 1999, The American journal of physiology.
[211] M. Volm,et al. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. , 1997, Anticancer research.
[212] N. Bouck,et al. How tumors become angiogenic. , 1996, Advances in cancer research.